AbCellera Biologics Inc. (ABCL)
The price, the headline numbers and the latest news, in one place.
AbCellera Biologics Inc. (ABCL) Stock Price, Analysis & Data
| Bid | 11.44 |
| Market Cap | 3.75B |
| Revenue (ttm) | 66.17M |
| Net Income (ttm) | -164.66M |
| 1.19 | |
| -0.52 | |
| n/a | |
| -16.18 | |
| P/B (ttm) | 3.96 |
| P/S (ttm) | 56.66 |
| Earnings Date | Nov 5, 2026 |
| Ask | 11.46 |
| Volume | 758,680 |
| Avg. Volume (20D) | 8,052,822 |
| Open | 11.57 |
| Previous Close | 11.57 |
| Day's Range | 11.23 - 11.80 |
| 52-Week Range | 2.75 - 12.15 |
| Analyst | Strong Buy |
| Price Target | 15 (29.87%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
Financial Performance
In 2025, AbCellera Biologics's revenue was 75.13M, an increase of 160.56% compared to the previous year's 28.83M. Earnings were -146.41M, a decrease of -10.1%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for ABCL stock is "Strong Buy". The 12-month stock price forecast is 15, which is upside of 29.87% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
